Product Availability Update for Gammaplex Immune Globulin
Gammaplex, an immune globulin, is indicated to treat chronic immune thrombocytopenic purpura (ITP) and primary humoral immunodeficiency.
Gammaplex, an immune globulin, is indicated to treat chronic immune thrombocytopenic purpura (ITP) and primary humoral immunodeficiency.
Bio Products Laboratory announced that the Food and Drug Administration (FDA) has approved Gammaplex 10% (immune globulin intravenous [human], 10% liquid) for the treatment of primary immunodeficiency (PI) and chronic immune thrombocytopenic purpura (ITP) in adults.
Shire announced the launch of Cuvitru (immune globulin subcutaneous [human], 20% solution) indicated as replacement therapy for primary humoral immunodeficiency (PI) in patients aged ≥2 years.
Some patients with primary immunodeficiency disorders may be at risk for rubella virus infection and possible serious skin inflammation after receiving the rubella vaccine, a study published in the Journal of Allergy and Clinical Immunology has found.
Shire announced that the Food and Drug Administration (FDA) has approved Cuvitru (immune globulin subcutaneous [human]) 20% solution for the treatment of primary immunodeficiency in patients aged ≥2 years.
Green Cross announced that the Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for IVIG-SN (human normal immunoglobulin G), for the treatment of primary immunodeficiency diseases (PID).
Green Cross announced that it has submitted its Biologics License Application (BLA) to the FDA for IVIG-SN (human normal immunoglobulin G) for the treatment of primary immunodeficiency diseases (PID).
A treatment taken by organ transplant patients to prevent organ rejection may help protect against Alzheimer’s disease.
Gene therapy may benefit children and teens with Wiskott-Aldrich syndrome, a rare immunodeficiency caused by mutations in the WAS gene.
CSL Behring announced that the Food and Drug Administration (FDA) has approved a new dosing option for Hizentra (immune serum globulin [human]) 0.2mg/mL (20%) Liquid to include treatment at regular intervals from daily to biweekly in patients with primary immunodeficiency.